¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Ascorbic Acid type SC"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • acid maltase
    »ê¼º¸»Å¸¾ÆÁ¦
  • acid mucopolysaccharide
    »ê¼ºÁ¡¾×´Ù´ç·ù, »ê¼º¹ÂÄÚ´Ù´ç·ù
  • acid phosphatase
    »ê¼ºÀλêºÐÇØÈ¿¼Ò
  • acid pyuria
    »ê¼º°í¸§´¢, »ê¼º³ó´¢
  • acid radical
    »ê±â, »ê¶óµðÄ®
  • acid rain
    »ê¼ººñ
  • acid salt
    »ê¿°
  • acid therapy
    »ê¿ä¹ý
  • acid-base compensation
    »ê¿°±âº¸»ó
  • acid-base equilibrium
    »ê¿°±âÆòÇü
  • acid-base indicator
    »ê¿°±âÁö½Ã°è
  • acid-fast
    Ç×»ê-
  • acid-fast bacillus
    Ç׻긷´ë±Õ, Ç×»ê±Õ
  • acid-fast bacterium
    Ç×»ê±Õ
  • acid-fast organism
    Ç×»ê±Õ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • acid burn
    »êÈ­»ó
  • acid dyspepsia
    À§»ê¼ÒÈ­ºÒ·®
  • acid fastness
    Ç׻꼺
  • acid mucopolysaccharide
    »ê¼ºÁ¡¾×´Ù´ç·ù
  • acid phosphatase
    »ê¼ºÀλêºÐÇØÈ¿¼Ò
  • acid pyuria
    »ê¼º°í¸§´¢, »ê¼º³ó´¢
  • acid radical
    »ê¼º±â, »ê±â
  • acid salt
    »ê¼º¿°
  • acid alcohol
    »ê¼º¾ËÄÚ¿Ã
  • acid challenge test
    »êÅõ¿©°Ë»ç
  • acid elution slide test
    »ê¿ëÃâ½½¶óÀ̵å°Ë»ç
  • acid fast organism
    Ç×»ê±Õ
  • acid lipase deficiency
    »ê¼ºÁöÁúºÐÇØÈ¿¼Ò°áÇÌ
  • acid-base compensation
    »ê¿°±âº¸»ó
  • acid-base equilibrium
    »ê¿°±âÆòÇü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • phage type
    ÆÄÁöÇü(¡­úþ).
  • phage type
    ÆÄÁöÇü
  • phased linear array type
    À§»óÂ÷ ¼±Çü ¹è¿­½Ä
  • phased linear array type
    À§»óÂ÷ ¹è¿­½Ä ¼±Çü (êÈßÓó¬ ÛÕÖªãÒ àÊû¡) Æ®·£½ºµà¼­
  • pilus, type 1
    Á¦1Çü ¼¶¸ð
  • plaque-type mutation
    ÇöóÅ©Çü µ¹¿¬º¯ÀÌ
  • platelet-type
    Ç÷¼ÒÆÇÇü(û¡)
  • pneumocyte type i
    È£ÈíÇãÆÄ²Ê¸®¼¼Æ÷
  • pneumocyte type ii
    °ú¸³ÇãÆÄ²Ê¸®¼¼Æ÷
  • precision type attachment
    Á¤¹ÐÇü¾îÅÂÄ¡ ¸ÕÆ®.
  • pyknic body type
    ºñ¸¸Çü ½ÅüÀ¯Çü
  • regular type
    ±ÔÄ¢Çü
  • 3,5-dinitrobenzoic acid
    3,5-µð´ÏÆ®·Îº¥Á¶»ê
  • 3-hydroxybutyric acid
    3-È÷µå·Ï½Ã³«»ê
  • 5-hydroxyindoleacetic acid
    5-È÷µå·Ï½ÃÀε¹¾Æ¼¼Æ®»ê, 5-È÷µå·Ï½ÃÀε¹ÃÊ»ê
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • hemoglobin C type
    CÇü Ç÷»ö¼Ò
  • hemoglobin E type
    E Çü Ç÷»ö¼Ò
  • hepatitis,type a
    A Çü
  • hepatitis,type b
    B Çü
  • herpes simplex virus type 1
    Á¦1Çü ´Ü¼øÆ÷Áø¹ÙÀÌ·¯½º
  • herpes simplex virus type 2
    Á¦2Çü ´Ü¼øÆ÷Áø¹ÙÀÌ·¯½º
  • htlv,type i
    type 1Çü
  • human T cell leukemia virus type I
    Á¦1Çü »ç¶÷ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • human T cell leukemia virus type I
    Á¦1Çü »ç¶÷ T¼¼Æ÷¹éÇ÷º´¹ÙÀÌ·¯½º
  • human T cell leukemia virus type II
    Á¦2Çü »ç¶÷ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • human T cell leukemia virus type II
    Á¦2Çü »ç¶÷ T¼¼Æ÷¹éÇ÷º´¹ÙÀÌ·¯½º
  • hutchinson-type neuroblastoma
    ÇãÄ£½¼(Hutchinson)Çü ½Å°æ¸ð¼¼Æ÷Á¾
  • hyperlipoproteinemia type III
    °íÁö´Ü¹éÇ÷Áõ III
  • hyperlipoproteinemia type IV
    °í´Ü¹éÇ÷Áõ IV Çü
  • hyperlipoprotenemia type II
    °íÁö´Ü¹éÇ÷Áõ II Çü
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • amino acid analyzer
    ¾Æ¹Ì³ë»ê(ß«) ºÐ¼®±â(ÝÂà°Ðï)
  • amino acid arm
    ¾Æ¹Ì³ë»ê ÆÈ
  • amino acid attachement site
    ¾Æ¹Ì³ë»ê(ß«) ºÎÂø(ݾó·)ÀÚ¸®
  • amino acid composition
    ¾Æ¹Ì³ë»ê Á¶¼º(ðÚà÷)
  • amino acid incorporation
    ¾Æ¹Ì³ë»ê(ß«) ÆíÀÔ(øºìý)
  • amino acid nitrogen
    ¾Æ¹Ì³ë»ê(ß«) Áú¼Ò(òòáÈ)
  • amino acid oxidase
    ¾Æ¹Ì³ë»ê(ß«) ¿Á½Ãµ¥À̽º
  • amino acid replacement
    ¾Æ¹Ì³ë»ê(ß«) ´ëü(ÓÛôð)
  • amino acid residue
    ¾Æ¹Ì³ë»ê(ß«) Àܱâ(íÑÐñ)
  • amino acid sequence
    ¾Æ¹Ì³ë»ê(ß«) ¼­¿­(ßíæê)
  • amino acid sequencer
    ¾Æ¹Ì³ë»ê(ß«) ¼­¿­°áÁ¤±â(ßíæê̽ïÒÐï)
  • amino acid side chain
    ¾Æ¹Ì³ë»ê(ß«) °ç»ç½½
  • amino acid starvation
    ¾Æ¹Ì³ë»ê(ß«) ±â¾Æ(ÑÆä»)
  • amino acid substitution
    ¾Æ¹Ì³ë»ê ġȯ(öÇüµ)
  • anthranilic acid
    ¾ÈÆ®¶ó´Ò»ê(ß«)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
DHA dehydroacetic acid; dehydroascorbic acid; dehydroepiandrosterone; dihydroacetic acid; dihydroxyaceto...
FA false aneurysm; Families Anonymous; Fanconi anemia; far advanced; fatty acid; febrile antigen; femor...
GA Gamblers Anonymous; gastric analysis; gastric antrum; general anesthesia; general angiography; gener...
IAA imidazoleacetic acid; indoleacetic acid; infectious agent, arthritis; insulin autoantibody; Internat...
NA Avogadro constant or number; nalidixic acid; Narcotics Anonymous; network administrator; neuraminida...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
AT1 A-II type 1
AT(1) ANG II type 1
AT(1) ANG II type 1 receptor
AT1R ANG II type 1 receptor
AT(2) ANG II type 2
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • sympathicotonic type
    ±³°¨½Å°æ ±äÀåÇü
  • target type
    ¸ñÇ¥¹° ÇüÅÂ
  • type A personality
    AÇü Àμº
  • type B personality
    BÇü Àμº
  • type cultural
    ´ëÇ¥ ±ÕÁ¾ ¹è¾ç, Ç¥ÁØ ¹è¾ç
  • type II
    2Çü
  • type III
    3Çü
  • type of eruption
    ¸ÍÃâÇü
  • type strain
    ´ëÇ¥ ±ÕÁ¾, Ç¥ÁØ ±ÕÁ¾
  • undulant type
    ÆÄ»óÇü
    ÆÄ»ó º¯µ¿À» Ư¡À¸·Î ÇÏ´Â Çü.
  • water in oil type
    À¯Áß¼öÀûÇü
  • Widman type flap
    WidmanÇü ÇÇÆÇ
  • wild type
    ¾ß»ýÇü
  • XY-type
    ¿¢½º¿ÍÀÌ Çü
    ¾Ï¼ö ¾î´À ÇÑÂÊÀÇ ¼º ¿°»öü Áß 1°³°¡ ´Ù¸¥ ¼º ¿°»öü¿Í Çü»óÀ» ´Þ¸®ÇÏ´Â »óÅ·μ­ ¼ºÀÌ °áÁ¤µÇ´Â °ÍÀ¸·Î, ÀÌ »ý¹°À» XY ÇüÀÇ »ý¹°À̶ó°í Çϸç, ¼öÄÆÀÌ ÀÌÇüÀÎ XYÇü , ¾ÏÄÆÀÌ ÀÌÇüÀÎ ZWÇüÀ¸·Î ±¸º°Çϱ⵵ ÇÑ´Ù.
  • 11-amino acid polypeptide
    11-¾Æ¹Ì³ë»ê Æú¸® ÆéŸÀ̵å
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
wild-type strain A strain found in nature or a standard strain.
See: auxotrophic strains, prototrophic strains.
(05 Mar 2000)
MPGN type i A kidney disorder which results in kidney dysfunction. Inflammation of the glomeruli result from an abnormal immune response and the deposition of antibodies within the kidney (glomerulus) ultrastructure. Membranoproliferative glomerulonephritis (MPGN) has been divided into two different types in the basis of where the antibodies are deposited in the glomerulus. MPGN type I, the more common type, deposits antibodies in the subendothelial layer of the basement membrane, whereas type II deposits antibodies in the bottom layer of the basement membrane.
Symptoms include cloudy urine (pyuria), decreased urine output, swelling and hypertension. This disorder often results in end-stage renal disease.
(27 Sep 1997)
mpgn type II A kidney disorder which results in kidney dysfunction. Inflammation of the glomeruli result from an abnormal immune response and the deposition of antibodies within the kidney (glomerulus) ultrastructure. Membranoproliferative glomerulonephritis (MPGN) has been divided into two different types in the basis of where the antibodies are deposited in the glomerulus. MPGN type I, the more common type, deposits antibodies in the subendothelial layer of the basement membrane, whereas type II deposits antibodies in the bottom layer of the basement membrane.
Symptoms include cloudy urine (pyuria), decreased urine output, swelling and hypertension. This disorder often results in end-stage renal disease.
(27 Sep 1997)
woodbury-type 1. A process in photographic printing, in which a relief pattern in gelatin, which has been hardened after certain operations, is pressed upon a plate of lead or other soft metal. An intaglio impression in thus produced, from which pictures may be directly printed, but by a slower process than in common printing.
2. A print from such a plate.
Origin: After the name of the inventor, W. Woodbury.
Source: Websters Dictionary
(01 Mar 1998)
multiple endocrine neoplasia type 1 A rare syndrome characterised by hyperplasia and/or neoplasms of the pituitary, parathyroid glands, and pancreatic islets. Hyperparathyroidism occurs in 90% of the cases and is usually the first manifestation of the syndrome. The most frequent pancreatic manifestation is gastrinoma typically leading to zollinger-ellison syndrome. The appearance of this condition has been limited to the loss of allelic heterozygosity at the 11q13 locus on the long arm of chromosome 11. Patients overall exhibit long survival times. Chemotherapy is rare and surgical management is generally dependent on the genetic expression in individual patients.
(12 Dec 1998)
multiple endocrine neoplasia type 2 <syndrome> This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor.
Incidence: approximately 3 in 100,000 people in the general population.
(27 Sep 1997)
multiple endocrine neoplasia type 2a A type of multiple endocrine neoplasia characterised by a virtually 100% incidence of medullary thyroid carcinoma, a 50% incidence of pheochromocytoma, and a lesser incidence of parathyroid adenomas associated with hyperparathyroidism. The condition is always transmitted through autosomal dominant inheritance. Genetic testing can identify individuals with the trait in early infancy. Treatment is usually excision of the enlarged parathyroid glands.
(12 Dec 1998)
multiple endocrine neoplasia type 2b A type of multiple endocrine neoplasia occurring as an isolated congenital presentation or as a distinct autosomal dominant disease. It is characterised by the 100% incidence of medullary thyroid carcinoma and frequent pheochromocytomas; patients seldom exhibit hyperparathyroidism. It is distinguished from men 2a by its characteristic physical appearance resulting from numerous neural defects including mucosal neuromas of the eyelids, lips, and tongue. The neural abnormalities also include widespread neurogangliomatosis of the gastrointestinal tract leading to abnormal gut motility. Treatment usually requires total thyroidectomy following evaluation for the presence of pheochromocytomas.
(12 Dec 1998)
multiple lipoprotein-type hyperlipidaemia <biochemistry> Inherited as a defective gene, this disorder is characterised by elevations in serum cholesterol and/or triglycerides. There are often multiple types of lipoproteins (LDL) elevated in one family. This condition is associated with an increased risk of cardiovascular disease.
Origin: Gr. Haima = blood
(27 Sep 1997)
contact-type dermatitis Dermatitis resembling contact dermatitis or eczema, but caused by an ingested or injected allergen, usually a drug, and with a widespread or generalised distribution.
(05 Mar 2000)
Cowdry's type A inclusion bodies Droplet-like masses of acidophilic material surrounded by clear halos within nuclei, with margination of chromatin on the nuclear membrane.
(05 Mar 2000)
Cowdry's type B inclusion bodies Droplet-like masses of acidophilic material surrounded by clear halos within nuclei, without other nuclear changes during early stages of development of the inclusion.
(05 Mar 2000)
habitat type <ecology> A land or aquatic unit, consisting of an aggregation of habitats having equivalent structure, function, and responses to disturbance.
(09 Oct 1997)
haemadsorption virus type 1 parainfluenza virus type 3
haemadsorption virus type 2 parainfluenza virus type 1
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • hypochlorous acid
    Â÷¾Æ¿°¼Ò»ê
  • hypophosphoric acid
    Â÷Àλê
  • hypophosphorous acid
    Â÷¾ÆÀλê
  • indoleacetic acid
    Àε¹ÃÊ»ê(½Ä¹°ÀÇ ¼ºÀå È£¸£¸ó)
  • inosinic acid
    À̳ë½Å»ê
  • iodic acid
    ¿ä¿Àµå»ê
  • isonicotinic acid hydrazide
    (¾à)À̼ҴÏÄÚÆ¾»ê ÇÏÀ̵å¶óÁöµå(°áÇÙ Ä¡·áÁ¦)
  • lactic acid
    À¯»ê
  • maleci acid
    ¸»·¹»ê
  • malic acid
    (È­) »ç°ú»ê
  • margaric acid
    ¸¶¸£°¡¸£»ê
  • methacrylic acid
    ¸ÞŸũ¸±»ê
  • muriatic acid
    ¿°»ê
  • naildixic acid
    (È­)³¯¸®µñ½Å»ê(ºñ´¢,»ý½Ä±â °¨¿°Áõ Ä¡·á¿ë Ç×»ý¹°Áú)
  • nitric acid
    Áú»ê
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á